Integra Lifesciences Holdings Corp (NASDAQ:IART) Short Interest Update

Integra Lifesciences Holdings Corp (NASDAQ:IART) was the target of a large growth in short interest in the month of June. As of June 30th, there was short interest totalling 1,446,600 shares, a growth of 29.7% from the May 30th total of 1,115,200 shares. Based on an average trading volume of 462,100 shares, the short-interest ratio is currently 3.1 days. Currently, 2.1% of the company’s shares are short sold.

IART has been the subject of a number of research reports. BidaskClub cut shares of Vertex Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Tuesday. ValuEngine cut shares of Acceleron Pharma from a “strong-buy” rating to a “buy” rating in a report on Thursday, April 18th. Oppenheimer lifted their price objective on shares of Chipotle Mexican Grill from $400.00 to $525.00 and gave the company an “underperform” rating in a report on Thursday, April 25th. Finally, Zacks Investment Research upgraded shares of Hanmi Financial from a “sell” rating to a “hold” rating in a report on Thursday, June 20th. Two investment analysts have rated the stock with a sell rating, seven have given a hold rating and five have given a buy rating to the company. The stock has a consensus rating of “Hold” and an average target price of $58.64.

NASDAQ IART traded down $0.51 on Friday, hitting $54.23. 240,746 shares of the stock were exchanged, compared to its average volume of 441,989. The company has a current ratio of 2.86, a quick ratio of 1.86 and a debt-to-equity ratio of 0.95. Integra Lifesciences has a fifty-two week low of $42.14 and a fifty-two week high of $66.41. The firm has a market cap of $4.64 billion, a P/E ratio of 22.41, a PEG ratio of 1.65 and a beta of 1.07. The firm has a 50-day simple moving average of $51.53.

Integra Lifesciences (NASDAQ:IART) last posted its quarterly earnings results on Wednesday, April 24th. The life sciences company reported $0.65 EPS for the quarter, topping the consensus estimate of $0.61 by $0.04. Integra Lifesciences had a net margin of 5.60% and a return on equity of 15.60%. The company had revenue of $359.69 million during the quarter, compared to analysts’ expectations of $361.12 million. During the same quarter in the previous year, the business posted $0.58 EPS. The firm’s revenue was up .7% on a year-over-year basis. Analysts forecast that Integra Lifesciences will post 2.7 EPS for the current fiscal year.

In other news, COO Glenn Coleman sold 3,650 shares of the business’s stock in a transaction that occurred on Friday, June 28th. The shares were sold at an average price of $55.00, for a total value of $200,750.00. Following the sale, the chief operating officer now directly owns 25,160 shares of the company’s stock, valued at approximately $1,383,800. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Christian S. Schade sold 15,658 shares of the business’s stock in a transaction that occurred on Friday, May 10th. The shares were sold at an average price of $51.56, for a total transaction of $807,326.48. The disclosure for this sale can be found here. 4.50% of the stock is currently owned by insiders.

Several institutional investors have recently modified their holdings of IART. Fort L.P. acquired a new position in shares of Integra Lifesciences in the 4th quarter valued at $34,000. Quadrant Capital Group LLC boosted its holdings in shares of Integra Lifesciences by 223.0% in the 1st quarter. Quadrant Capital Group LLC now owns 646 shares of the life sciences company’s stock valued at $34,000 after buying an additional 446 shares in the last quarter. Executive Wealth Management LLC acquired a new position in shares of Integra Lifesciences in the 4th quarter valued at $38,000. Captrust Financial Advisors boosted its holdings in shares of Integra Lifesciences by 43.6% in the 4th quarter. Captrust Financial Advisors now owns 2,330 shares of the life sciences company’s stock valued at $105,000 after buying an additional 707 shares in the last quarter. Finally, NumerixS Investment Technologies Inc boosted its holdings in shares of Integra Lifesciences by 100.1% in the 4th quarter. NumerixS Investment Technologies Inc now owns 2,801 shares of the life sciences company’s stock valued at $124,000 after buying an additional 1,401 shares in the last quarter. Institutional investors and hedge funds own 82.27% of the company’s stock.

About Integra Lifesciences

Integra LifeSciences Holdings Corporation develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, orthopedics, and general surgery. The company operates in two segments, Codman Specialty Surgical, and Orthopedics and Tissue Technologies.

Further Reading: Terms to Better Understand Call Options

Receive News & Ratings for Integra Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.